Crinetics Q1 Revenue $10.73M, Beats Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy CRNX?
Reports Q1 revenue $10.73M, consensus $8.52M. "We are extremely pleased with the significant impact that Palsonify is making across the community. This is illustrated by the strong adoption of Palsonify by healthcare providers and the positive patient response to treatment," said Scott Struthers, founder and chief executive officer of Crinetics. "The significant growth in our unique prescriber base reflects a growing confidence among endocrinologists in the compelling clinical data and proven efficacy of Palsonify. Expanding clinical adoption is fueling sustained demand, evidenced by the steady growth trend in new patient start forms. We are seeing an increasingly efficient path to treatment for patients as the reimbursement environment matures. These results reinforce our confidence in the long-term commercial trajectory of Palsonify and our ability to deliver transformative therapies at scale."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRNX
Wall Street analysts forecast CRNX stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 43.490
Low
67.00
Averages
89.40
High
105.00
Current: 43.490
Low
67.00
Averages
89.40
High
105.00
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Crinetics Pharmaceuticals Q1 2026 Earnings Call Highlights
- Patient Enrollment Surge: Crinetics reported 232 new patient enrollments in Q1 2026, driving net product revenue to $10.3 million, indicating increasing market acceptance of Palsonify, which is on track to become the preferred treatment for acromegaly.
- International Regulatory Progress: The company received MAA approval from the European Commission and submitted applications in Japan and Brazil, demonstrating a strategic push for international market expansion that is expected to lay the groundwork for future revenue growth.
- Reimbursement Coverage Improvement: Approximately 70% of patients were reimbursed by the end of Q1, with a goal to exceed 75% coverage by Q3 2026, which will enhance market competitiveness and increase patient adoption.
- Stable Financial Outlook: Despite R&D expenses reaching $100.1 million in Q1, the company projects that its existing cash and investments will fund operations into 2030, reflecting financial health and ongoing investment capability.
See More
Crinetics Pharmaceuticals: Stock Potential Analysis
- Investment Return Potential: Crinetics Pharmaceuticals (NASDAQ:CRNX) first appeared in Farallon Capital's 13F portfolio in Q3 2018 with over 141,000 shares, indicating early confidence in the investment.
- Holding Dynamics: By early 2019, the fund completely sold off its stake, but reopened a position in Q3 2023, with the latest disclosure showing nearly 500,000 shares in Q2 2024, reflecting sustained interest in the company.
- Optimistic Market Outlook: Crinetics' PALSONIFY received European Commission approval, becoming the only once-daily oral treatment on the market, with projected revenues of $62 million in 2026, significantly exceeding original consensus estimates, indicating rapid market acceptance of its product.
- Increased Hedge Fund Confidence: Early data shows a 5% adoption rate for PALSONIFY within months of launch, suggesting that hedge funds are optimistic about Crinetics' future growth, which could drive stock price increases.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Crinetics' PALSONIFY Receives EU Approval for Acromegaly Treatment
- Drug Approval: Crinetics Pharmaceuticals announced that its oral drug PALSONIFY (Paltusotine) has received approval from the European Commission for the treatment of adult patients with acromegaly, marking its legal launch across 27 EU member states and 3 EEA countries.
- Clinical Trial Results: The approval of PALSONIFY is based on data from two pivotal Phase 3 trials, PATHFNDR-1 and PATHFNDR-2, which demonstrated rapid onset, reliable biochemical control, and sustained efficacy in both medically untreated and previously treated patients.
- Market Potential: Following FDA approval in Q4 2025, PALSONIFY generated net product revenue of $5.4 million, indicating strong market potential, while Crinetics reported cash and investment securities totaling $1.0 billion, providing ample funding for future R&D.
- Stock Performance: CRNX shares have traded between $25.83 and $57.99 over the past year, closing at $38.62 on Monday with a 0.76% increase, although down 1.61% to $38.00 in after-hours trading, reflecting a positive market response to the new drug approval.
See More
PALSONIFY Approved in EU for Acromegaly Treatment
- First Approval: Crinetics' PALSONIFY becomes the first once-daily oral therapy approved in the EU for acromegaly, marking a significant step in establishing the company's leadership in the global endocrinology sector.
- Clinical Data Support: The approval is based on pivotal Phase 3 trials, PATHFNDR-1 and PATHFNDR-2, demonstrating significant biochemical control and symptom relief, enhancing its competitive edge in the market.
- Market Launch Plans: Crinetics plans initial commercialization efforts in Germany and Austria, which are expected to rapidly address the treatment needs for acromegaly in these regions, thereby increasing the company's influence in the European market.
- International Collaboration: Crinetics is partnering with Japan's Sanwa Kagaku Kenkyusho to develop PALSONIFY, having applied for orphan drug designation in Japan, reflecting its strategic intent for global expansion.
See More
Neutrolis Appoints New Chief Business & Strategy Officer
- Leadership Change: Neutrolis has appointed Caren Deardorf as Chief Business & Strategy Officer, tasked with advancing NTR-1011 for autoimmune diseases, indicating the company's strategic focus on clinical pipeline progression.
- Extensive Industry Experience: Deardorf brings over 30 years of leadership experience in biopharma, having held executive roles at Editas Medicine and Biogen, where she successfully led multiple global product launches, enhancing Neutrolis's market competitiveness.
- Strategic Vision and Execution: Neutrolis CEO Anthony Aiudi praised Deardorf's commercial acuity and strategic vision, emphasizing that her leadership will be crucial for advancing the company's pipeline and expanding strategic partnerships, signaling future growth potential.
- Innovative Therapeutic Approach: Neutrolis focuses on developing rapid-acting, non-immunosuppressive therapies targeting Neutrophil Extracellular Traps (NETs), and Deardorf's addition is expected to accelerate the clinical application of this innovative therapy, addressing urgent needs in autoimmune disease patients.
See More
Crinetics Pharmaceuticals Q1 2026 Earnings Call Highlights
- Patient Enrollment Surge: Crinetics reported 232 new patient enrollments in Q1 2026, driving net product revenue to $10.3 million, indicating increasing market acceptance of Palsonify, which is on track to become the preferred treatment for acromegaly.
- International Regulatory Progress: The company received MAA approval from the European Commission and submitted applications in Japan and Brazil, demonstrating a strategic push for international market expansion that is expected to lay the groundwork for future revenue growth.
- Reimbursement Coverage Improvement: Approximately 70% of patients were reimbursed by the end of Q1, with a goal to exceed 75% coverage by Q3 2026, which will enhance market competitiveness and increase patient adoption.
- Stable Financial Outlook: Despite R&D expenses reaching $100.1 million in Q1, the company projects that its existing cash and investments will fund operations into 2030, reflecting financial health and ongoing investment capability.
See More
Crinetics Pharmaceuticals: Stock Potential Analysis
- Investment Return Potential: Crinetics Pharmaceuticals (NASDAQ:CRNX) first appeared in Farallon Capital's 13F portfolio in Q3 2018 with over 141,000 shares, indicating early confidence in the investment.
- Holding Dynamics: By early 2019, the fund completely sold off its stake, but reopened a position in Q3 2023, with the latest disclosure showing nearly 500,000 shares in Q2 2024, reflecting sustained interest in the company.
- Optimistic Market Outlook: Crinetics' PALSONIFY received European Commission approval, becoming the only once-daily oral treatment on the market, with projected revenues of $62 million in 2026, significantly exceeding original consensus estimates, indicating rapid market acceptance of its product.
- Increased Hedge Fund Confidence: Early data shows a 5% adoption rate for PALSONIFY within months of launch, suggesting that hedge funds are optimistic about Crinetics' future growth, which could drive stock price increases.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Crinetics' PALSONIFY Receives EU Approval for Acromegaly Treatment
- Drug Approval: Crinetics Pharmaceuticals announced that its oral drug PALSONIFY (Paltusotine) has received approval from the European Commission for the treatment of adult patients with acromegaly, marking its legal launch across 27 EU member states and 3 EEA countries.
- Clinical Trial Results: The approval of PALSONIFY is based on data from two pivotal Phase 3 trials, PATHFNDR-1 and PATHFNDR-2, which demonstrated rapid onset, reliable biochemical control, and sustained efficacy in both medically untreated and previously treated patients.
- Market Potential: Following FDA approval in Q4 2025, PALSONIFY generated net product revenue of $5.4 million, indicating strong market potential, while Crinetics reported cash and investment securities totaling $1.0 billion, providing ample funding for future R&D.
- Stock Performance: CRNX shares have traded between $25.83 and $57.99 over the past year, closing at $38.62 on Monday with a 0.76% increase, although down 1.61% to $38.00 in after-hours trading, reflecting a positive market response to the new drug approval.
See More
PALSONIFY Approved in EU for Acromegaly Treatment
- First Approval: Crinetics' PALSONIFY becomes the first once-daily oral therapy approved in the EU for acromegaly, marking a significant step in establishing the company's leadership in the global endocrinology sector.
- Clinical Data Support: The approval is based on pivotal Phase 3 trials, PATHFNDR-1 and PATHFNDR-2, demonstrating significant biochemical control and symptom relief, enhancing its competitive edge in the market.
- Market Launch Plans: Crinetics plans initial commercialization efforts in Germany and Austria, which are expected to rapidly address the treatment needs for acromegaly in these regions, thereby increasing the company's influence in the European market.
- International Collaboration: Crinetics is partnering with Japan's Sanwa Kagaku Kenkyusho to develop PALSONIFY, having applied for orphan drug designation in Japan, reflecting its strategic intent for global expansion.
See More
Neutrolis Appoints New Chief Business & Strategy Officer
- Leadership Change: Neutrolis has appointed Caren Deardorf as Chief Business & Strategy Officer, tasked with advancing NTR-1011 for autoimmune diseases, indicating the company's strategic focus on clinical pipeline progression.
- Extensive Industry Experience: Deardorf brings over 30 years of leadership experience in biopharma, having held executive roles at Editas Medicine and Biogen, where she successfully led multiple global product launches, enhancing Neutrolis's market competitiveness.
- Strategic Vision and Execution: Neutrolis CEO Anthony Aiudi praised Deardorf's commercial acuity and strategic vision, emphasizing that her leadership will be crucial for advancing the company's pipeline and expanding strategic partnerships, signaling future growth potential.
- Innovative Therapeutic Approach: Neutrolis focuses on developing rapid-acting, non-immunosuppressive therapies targeting Neutrophil Extracellular Traps (NETs), and Deardorf's addition is expected to accelerate the clinical application of this innovative therapy, addressing urgent needs in autoimmune disease patients.
See More
